Urinary Retention After Arthroplasty
Launched by CENTRAL FINLAND HOSPITAL DISTRICT · Jan 11, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how we can safely monitor when patients start to urinate on their own after having knee replacement surgery, also known as arthroplasty. After this type of surgery, some patients may have trouble urinating, which can lead to the need for a catheter (a tube placed in the bladder). The study aims to see if we can rely on patients’ symptoms alone, rather than using an ultrasound machine to check for urine in the bladder, to determine when they can urinate without help.
To participate in this trial, you would need to be scheduled for a total knee replacement surgery and be between the ages of 65 and 74. However, if you have had previous surgery for bladder cancer, are having surgery due to a fracture, or have other specific conditions that affect your urinary system, you may not be eligible. If you join the study, you can expect to be monitored closely after your surgery to see if you can urinate independently based on your symptoms. This research is important because it could help reduce the use of catheters, which can lead to infections and other complications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • elective total knee arthroplasty
- Exclusion Criteria:
- • previous surgery for urologic cancer
- • fracture as indication for surgery
- • lack of co-operation
- • untreated urinary retention
- • nephrostoma
- • general anesthesia
About Central Finland Hospital District
Central Finland Hospital District is a leading healthcare organization dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to the highest standards of ethical practice and scientific rigor, the district collaborates with a network of healthcare professionals and researchers to facilitate cutting-edge studies across various medical fields. With a focus on enhancing treatment outcomes and fostering health advancements, Central Finland Hospital District plays a pivotal role in translating research findings into practical applications that benefit the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jyväskylä, , Finland
Patients applied
Trial Officials
Juha Paloneva, professor
Principal Investigator
Chief medical director
Heikki Seikkula, PhD
Study Chair
Investigator
Juho Sippola, MD
Study Chair
Investigator
Konsta Pamilo, PhD
Study Chair
Investigator
Jonne Åkerla, MD
Study Chair
Investigator
Aleksi Reito, PhD
Study Chair
Investigator
Pirkko Kinnunen
Study Chair
Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials